Mon.Mar 25, 2024

article thumbnail

STAT+: During the pandemic, were great vaccines bad business? A company-by-company review

STAT

It’s been four years since Covid-19 emerged, igniting a pandemic that killed millions of people and brought the world to its knees. A key factor in taming the pandemic was the creation of effective vaccines , which have saved millions of lives. You’d think developing a successful vaccine would be an unmitigated win, from a financial perspective.

Vaccines 363
article thumbnail

Who’s getting left behind in the weight loss bonanza?

PharmaVoice

As the new weight loss drugs take the world by storm, companies in other areas are battening the hatches for when slimmer patients need fewer medical interventions.

279
279
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

STAT+: Nvidia says generative AI will revolutionize health care. So did IBM, with Dr. Watson

STAT

The health care sector is a notorious laggard when it comes to technology. It was slow to use computers, digitize patient data, and share information electronically. While most of the world instantly interacts via Zoom and Slack, hospitals — even today — are still sending faxes. But something different is happening with generative AI. Health systems, drugmakers, and insurers are racing to build the technology into their operations, aligning themselves with corporate giants such as

Hospitals 360
article thumbnail

Why a pharmacist was tapped to spearhead ‘patient excellence’ at Boehringer Ingelheim

PharmaVoice

Deborah Reardon is leading a new pillar that asks, ‘Are we looking at this from a patient lens and not from a Boehringer lens?

245
245
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Disparities in donor acceptance rates point to need for more equitable heart transplant care

STAT

When a patient is going through end-stage heart failure, the best treatment is to get a heart transplant. The basic steps are familiar: First a patient gets on the waiting list, and then the wait begins for the offers. In recent years, access to donor hearts has gone up thanks to a change in heart allocation policy, but there are still gender- and race-based disparities in the acceptance rate of a donor heart offer by transplant teams, according to new research published Monday in the Journal of

363
363
article thumbnail

FDA rejects Regeneron lymphoma drug, setting back company’s oncology push

BioPharma Dive

The agency wants Regeneron to make more progress with a confirmatory trial before clearing odronextamab, a “bispecific” antibody being developed for multiple blood cancers.

116
116

More Trending

article thumbnail

FDA approves AstraZeneca’s Ultomiris for NMOSD treatment

Pharmafile

AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvs) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD). This approval follows positive results from the phase 3 CHAMPION-NMOSD trial, which were published in […] The post FDA approves AstraZeneca’s Ultomiris for NMOSD treatment appeared fir

111
111
article thumbnail

STAT+: Novo Nordisk to acquire heart disease-focused Cardior Pharmaceuticals in deal worth $1.1 billion

STAT

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.   Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

327
327
article thumbnail

Novo Nordisk agrees $1.1bn takeover of RNA biotech Cardior

pharmaphorum

Novo Nordisk has agreed to buy Cardior Pharmaceuticals for $1.1 billion, adding expertise in RNA therapeutics and a heart failure therapy in mid-stage trials.

122
122
article thumbnail

STAT+: Patient advocates clash over wisdom of ‘approving drugs faster and faster’

STAT

NEW YORK — Over 30 years ago, Gregg Gonsalves and other AIDS activists persuaded Congress to create the accelerated approval pathway, allowing regulators to speed access to drugs for thousands of dying patients. These days, though, Gonsalves sounds uneasy — if not mournful — of the world he helped build.  “We’re approving drugs faster and faster — [the FDA is] one of the fastest regulatory agencies in the world — we know less and less about t

338
338
article thumbnail

Why Every Small Business Needs an HCM Solution: A Comprehensive Guide

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

article thumbnail

Pharmacy First: Tips for diagnosing and treating uncomplicated UTI in women

The Pharmacist

CLINICAL UPDATE How are you getting on with Pharmacy First? GP Dr Toni Hazell presents useful tips for diagnosing and treating uncomplicated UTI in women Most community pharmacies in England are now running the Pharmacy First service which enables them to diagnose and treat seven specific conditions. Under the service, pharmacists can prescribe set medications […] The post Pharmacy First: Tips for diagnosing and treating uncomplicated UTI in women appeared first on The Pharmacist.

article thumbnail

Opinion: Methadone treatment has been reformed for the better. States shouldn’t go back to the old ways

STAT

Since the Food and Drug Administration approved methadone for treating opioid use disorder in 1972, its distribution has been strictly regulated. The regulations were put in place to ensure public and patient safety. But they made it hard for people to get the treatment they need. Until recently, most people had to visit a methadone clinic in person for an initial exam and then come in five to six days a week to take their doses under the watchful eye of a health care professional.

313
313
article thumbnail

FDA approves nonsteroidal treatment for Duchenne muscular dystrophy

World Pharma News

The U.S. Food and Drug Administration approved Duvyzat (givinostat) oral medication for the treatment of Duchenne Muscular Dystrophy (DMD) in patients six years of age and older. Duvyzat is the first nonsteroidal drug approved to treat patients with all genetic variants of DMD. It is a histone deacetylase (HDAC) inhibitor that works by targeting pathogenic processes to reduce inflammation and loss of muscle.

119
119
article thumbnail

STAT+: Medicare Advantage insurers pressure Biden administration for bigger payments

STAT

The public will soon find out whether the federal government is willing to meet the health insurance industry’s demands and deposit more money into the bank accounts of next year’s Medicare Advantage plans. Budget officials within the Biden administration started reviewing final payment regulations for 2025 Medicare Advantage plans last week after more than 42,000 public comments rolled into the federal government’s inbox.

278
278
article thumbnail

Best Practices to Streamline Compensation Management: A Foundation for Growth

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

article thumbnail

Ask patients about any fever or rash to stop measles, says NHSE

The Pharmacist

Patients should be asked about any fever or rash in a bid to stop the spread of measles, new guidance from NHS England (NHSE) says. All staff must also know that non-immunised individuals with these symptoms should be isolated on arrival in the building under the advice which notes that ‘measles is highly infectious and […] The post Ask patients about any fever or rash to stop measles, says NHSE appeared first on The Pharmacist.

Vaccines 117
article thumbnail

STAT+: Pharmalittle: We’re reading about a Novo Nordisk deal, a Regeneron setback, and more

STAT

Good morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, because that oh-so familiar routine of online meetings, phone calls, and deadlines has predictably returned. But you knew this would happen, yes? After all, the world, such as it is, continues to spin. So time to give it a nudge in a better direction with a cup or two of stimulation.

Diabetes 278
article thumbnail

FDA turns down Regeneron bispecific blood cancer antibody

pharmaphorum

FDA has turned down a pair of marketing applications for Regeneron’s CD20xCD3 bispecific antibody odronextamab to treat two common forms of non-Hodgkin lymphoma

111
111
article thumbnail

How will the Supreme Court’s mifepristone decision impact biopharma?

STAT

New biotech newsletter launching this Thursday. Don’t miss out. Hey there. Today, we discuss the implications of the Supreme Court’s forthcoming mifepristone evaluation on the FDA and the biopharma industry. We also examine how Covid-19 vaccine makers are faring today, and more.

Vaccines 278
article thumbnail

Enhance Healthcare Efficiency With Top Payroll & HCM Services

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

article thumbnail

NICE endorses use of digital therapies for psychosis

pharmaphorum

Three digital health technologies (DHTs) used to support patients with psychosis can be used by the NHS while additional evidence of their benefits is gathered.

115
115
article thumbnail

STAT+: Vertex Pharmaceuticals is considering relocating its headquarters

STAT

When Vertex Pharmaceuticals moved from Cambridge to Boston’s Seaport a decade ago, it signaled that what was then a sea of parking lots could be a booming business district, and galvanized a wave of new development. Now, Vertex may be on the move again. With the lease on its two-building campus on Fan Pier set to expire in 2028, the company is reevaluating its real estate options — and considering leaving its prominent headquarters for another spot in the neighborhood.

article thumbnail

Astellas breaks ground on new facility

European Pharmaceutical Review

Astellas Ireland, a wholly owned subsidiary of Astellas, has officially marked the start of construction of a new €330 million manufacturing facility at Kerry Technology Park in Tralee, Ireland. The ground-breaking ceremony, held on 25 March, was attended by Irish government officials as well as project partners and senior executives from Astellas. The new 17,000 square meter state-of-the-art facility will accelerate the expansion of Astellas’ in-house manufacturing capabilities, including for a

article thumbnail

Altamira Therapeutics partners with Univercells Group on nanoparticle-delivered mRNA vaccines

Express Pharma

Under the terms of the agreement, Univercells will test in vitro and in vivo a proprietary mRNA vaccine delivered with Altamira’s SemaPhore nanoparticle platform Altamira Therapeutics, a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets has announced that it has entered into a collaboration agreement with Univercells Group to evaluate the use of the Company’s proprietary SemaPhore platform for the delivery of mRNA vaccines.

Vaccines 102
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

CHMP backs Novartis’ Fabhalta as first oral therapy for PNH

pharmaphorum

The March meeting of the EMA’s human medicines committee saw an approval recommendation for Novartis’ Fabhalta, on track to become the first oral monotherapy for rare disease paroxysmal nocturnal haemoglobinuria (PNH) in the EU.

104
104
article thumbnail

Novo Nordisk to acquire Cardior Pharmaceuticals to strengthen pipeline in cardiovascular disease

Express Pharma

The agreement includes Cardior’s lead compound CDR132L, currently in phase 2 clinical development for the treatment of heart failure Novo Nordisk and Cardior Pharmaceuticals has announced that Novo Nordisk has agreed to acquire Cardior for up to 1.025 billion Euros, including an upfront payment and additional payments if certain development and commercial milestones are achieved.

article thumbnail

FDA approves J&J’s OPSYNVI for pulmonary arterial hypertension

Pharmaceutical Technology

The US FDA approved Johnson & Johnson's (J&J) OPSYNVI for chronic treatment in adult patients with pulmonary arterial hypertension.

98
article thumbnail

Automatic records updates from pharmacies to GPs to be phased in from this week

The Pharmacist

An IT functionality that will enable pharmacists to automatically update GP records with Pharmacy First consultations will be rolled out in a ‘phased’ manner from this week. But the speed of the roll-out will largely depend on the readiness of pharmacy IT systems, one GP system provider has suggested. At the time of publishing, one […] The post Automatic records updates from pharmacies to GPs to be phased in from this week appeared first on The Pharmacist.

101
101
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Cancer Research UK and CRIS fund lung cancer vaccine research

Pharmaceutical Technology

Cancer Research UK and the CRIS Cancer Foundation have awarded a £1.7m ($2.1m) grant for developing the lung cancer vaccine LungVax.

article thumbnail

Cluepoints on overvcoming scepticism and the benefits of AI to optimize trial strategies

Outsourcing Pharma

Patrick Hughes, co-founder and chief commercial officer of Cluepoints and OSP was able to catch up for an in-person during SCOPE 2024 to find out what developments the company had been working on and how they are benefiting from using AI.

83
article thumbnail

Elahere secures full approval from FDA for types of ovarian cancer

Pharmaceutical Technology

The FDA granted accelerated approval for the drug back in November 2022, and granted priority review in December 2023.

98
article thumbnail

With 90% of rare disease patients feeling depressed, what can be done?

Outsourcing Pharma

The Undiagnosed Diseases Network Foundation (UDNF) has successfully co-led a critical discussion on mental health at the 2024 Rare Disease Summit.

89
article thumbnail

Axsome drug succeeds in narcolepsy symptoms trial

BioPharma Dive

Despite the late-stage victory, shares of the New York-based biotech dipped more than 3%. One analyst argued that Axsome’s drug has “largely been falling under investor radars.

69